Demonstrating short-term efficacy is no longer enough, regulators increasingly require a clear understanding of long-term outcomes and benefit–risk balance. Translating Phase 3 trial data into long-term, real-world insights remains a major challenge, particularly when evaluating trade-offs between disease progression and treatment-related adverse events.
Download our case study to learn how advanced modelling and simulation approaches extend trial data beyond its original scope, helping organizations address regulatory uncertainty and support successful label definition.
What You’ll Learn
In this case study, you’ll discover how a leading pharmaceutical organization:
Extended Phase 3 trial data using integrated disease progression modelling
Simulated long-term benefit–risk outcomes across multiple treatment strategies
Quantified trade-offs between disease progression and adverse events
Combined randomized controlled trial and real-world data for stronger evidence generation
Identified optimal patient subgroups to support regulatory positioning and label strategy
